Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EWTXNASDAQ:JANXNASDAQ:KMDANASDAQ:SPRY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEWTXEdgewise Therapeutics$14.32+0.8%$15.43$10.60▼$38.12$1.51B0.361.18 million shs955,353 shsJANXJanux Therapeutics$24.24-3.9%$27.79$22.48▼$71.71$1.43B3.24875,689 shs1.27 million shsKMDAKamada$6.95+4.8%$6.58$4.74▼$9.16$399.49M0.9490,818 shs136,507 shsSPRYARS Pharmaceuticals$14.62-2.4%$13.68$7.55▼$18.51$1.44B0.841.26 million shs1.23 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEWTXEdgewise Therapeutics0.00%-3.92%-4.25%-43.34%-16.95%JANXJanux Therapeutics0.00%+4.34%-18.78%-22.82%-44.41%KMDAKamada0.00%-2.79%-0.90%-5.56%+25.09%SPRYARS Pharmaceuticals0.00%+5.05%+8.79%+41.86%+66.82%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEWTXEdgewise Therapeutics2.9726 of 5 stars4.41.00.00.03.13.30.0JANXJanux Therapeutics2.2263 of 5 stars3.50.00.00.04.13.30.0KMDAKamada3.8481 of 5 stars3.43.00.00.03.41.73.1SPRYARS Pharmaceuticals2.3657 of 5 stars3.60.00.00.02.34.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEWTXEdgewise Therapeutics 2.78Moderate Buy$40.22180.88% UpsideJANXJanux Therapeutics 3.09Buy$95.25292.95% UpsideKMDAKamada 2.75Moderate Buy$14.67111.03% UpsideSPRYARS Pharmaceuticals 3.17Buy$31.00112.04% UpsideCurrent Analyst Ratings BreakdownLatest KMDA, EWTX, JANX, and SPRY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025KMDAKamadaBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.005/8/2025KMDAKamadaSidotiSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold4/30/2025EWTXEdgewise TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$41.004/21/2025EWTXEdgewise TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$43.00 ➝ $43.004/3/2025EWTXEdgewise TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$56.00 ➝ $52.004/2/2025EWTXEdgewise TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$51.00 ➝ $51.004/2/2025EWTXEdgewise TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeSector Outperform ➝ Sector Perform$50.00 ➝ $14.003/21/2025KMDAKamadaBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$15.003/7/2025EWTXEdgewise TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Outperform$50.003/7/2025SPRYARS PharmaceuticalsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Outperform$30.003/6/2025KMDAKamadaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00 ➝ $11.00(Data available from 5/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEWTXEdgewise TherapeuticsN/AN/AN/AN/A$4.53 per shareN/AJANXJanux Therapeutics$9.34M153.64N/AN/A$7.46 per share3.25KMDAKamada$167.24M2.39$0.39 per share17.90$4.25 per share1.64SPRYARS Pharmaceuticals$97.12M14.78N/AN/A$2.40 per share6.09Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEWTXEdgewise Therapeutics-$100.16M-$1.55N/AN/AN/AN/A-26.83%-25.67%8/14/2025 (Estimated)JANXJanux Therapeutics-$58.29M-$1.36N/AN/AN/A-463.91%-10.47%-9.86%8/6/2025 (Estimated)KMDAKamada$8.28M$0.2924.8221.720.979.92%6.30%4.49%8/13/2025 (Estimated)SPRYARS Pharmaceuticals-$54.37M-$0.16N/AN/AN/AN/A-22.56%-21.82%8/5/2025 (Estimated)Latest KMDA, EWTX, JANX, and SPRY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025KMDAKamada$0.07$0.07N/A$0.07$154.06 million$44.02 million5/14/2025Q1 2025SPRYARS Pharmaceuticals-$0.35-$0.35N/A-$0.35$7.48 million$7.97 million5/8/2025Q1 2025EWTXEdgewise Therapeutics-$0.45-$0.43+$0.02-$0.43N/AN/A5/8/2025Q1 2025JANXJanux Therapeutics-$0.43-$0.38+$0.05-$0.38$0.59 millionN/A3/20/2025Q4 2024SPRYARS Pharmaceuticals-$0.04$0.52+$0.56$0.52$15.46 million$86.58 million3/3/2025Q4 2024EWTXEdgewise Therapeutics-$0.39-$0.42-$0.03-$0.42N/AN/A2/27/2025Q4 2024JANXJanux Therapeutics-$0.49-$0.36+$0.13-$0.36N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEWTXEdgewise TherapeuticsN/AN/AN/AN/AN/AJANXJanux TherapeuticsN/AN/AN/AN/AN/AKMDAKamadaN/AN/AN/AN/AN/ASPRYARS PharmaceuticalsN/AN/AN/AN/AN/ALatest KMDA, EWTX, JANX, and SPRY DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date3/5/2025KMDAKamada--$0.203/17/20253/17/20254/7/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEWTXEdgewise TherapeuticsN/A26.3526.35JANXJanux TherapeuticsN/A38.8038.80KMDAKamadaN/A4.842.73SPRYARS PharmaceuticalsN/A12.5612.52Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEWTXEdgewise TherapeuticsN/AJANXJanux Therapeutics75.39%KMDAKamada20.38%SPRYARS Pharmaceuticals68.16%Insider OwnershipCompanyInsider OwnershipEWTXEdgewise Therapeutics23.20%JANXJanux Therapeutics8.10%KMDAKamada36.10%SPRYARS Pharmaceuticals33.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEWTXEdgewise Therapeutics60105.20 million71.86 millionOptionableJANXJanux Therapeutics3059.18 million37.05 millionOptionableKMDAKamada36057.48 million36.73 millionOptionableSPRYARS Pharmaceuticals9098.21 million58.21 millionOptionableKMDA, EWTX, JANX, and SPRY HeadlinesRecent News About These CompaniesARS Pharmaceuticals to Participate in Upcoming Investor ConferencesMay 27 at 8:00 AM | globenewswire.comMillennium Management LLC Acquires 452,532 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)May 26 at 3:53 AM | marketbeat.comARS Pharmaceuticals (NASDAQ:SPRY) Downgraded by Wall Street Zen to SellMay 24 at 11:53 AM | marketbeat.comWoodline Partners LP Purchases 133,276 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)May 24 at 5:02 AM | marketbeat.comNorthern Trust Corp Increases Stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)May 24 at 3:18 AM | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives Average Recommendation of "Buy" from AnalystsMay 24 at 1:05 AM | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) CFO Kathleen D. Scott Sells 50,000 SharesMay 23, 2025 | insidertrades.comRafferty Asset Management LLC Increases Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)May 23, 2025 | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives Consensus Recommendation of "Buy" from BrokeragesMay 22, 2025 | americanbankingnews.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock Position Raised by Wexford Capital LPMay 21, 2025 | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Sold by The Manufacturers Life Insurance CompanyMay 21, 2025 | marketbeat.comFY2025 EPS Estimates for SPRY Cut by Cantor FitzgeraldMay 20, 2025 | marketbeat.comCantor Fitzgerald Has Weak Estimate for SPRY FY2025 EarningsMay 20, 2025 | americanbankingnews.comQ2 EPS Estimate for ARS Pharmaceuticals Reduced by AnalystMay 20, 2025 | americanbankingnews.comLeerink Partnrs Has Bearish Outlook for SPRY Q2 EarningsMay 20, 2025 | marketbeat.comWilliam Blair Brokers Lower Earnings Estimates for SPRYMay 20, 2025 | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Sold by Jacobs Levy Equity Management Inc.May 19, 2025 | marketbeat.comPrice T Rowe Associates Inc. MD Reduces Holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)May 19, 2025 | marketbeat.comEquities Analysts Set Expectations for SPRY Q2 EarningsMay 19, 2025 | americanbankingnews.comEarnings call transcript: ARS Pharmaceuticals Q1 2025 revenue beats forecastMay 16, 2025 | uk.investing.comPanoramic Capital LLC Takes Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)May 16, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKMDA, EWTX, JANX, and SPRY Company DescriptionsEdgewise Therapeutics NASDAQ:EWTX$14.32 +0.11 (+0.77%) Closing price 04:00 PM EasternExtended Trading$14.19 -0.13 (-0.91%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.Janux Therapeutics NASDAQ:JANX$24.24 -0.98 (-3.89%) Closing price 04:00 PM EasternExtended Trading$23.92 -0.32 (-1.30%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.Kamada NASDAQ:KMDA$6.95 +0.32 (+4.83%) Closing price 04:00 PM EasternExtended Trading$6.98 +0.03 (+0.45%) As of 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.ARS Pharmaceuticals NASDAQ:SPRY$14.62 -0.36 (-2.40%) Closing price 04:00 PM EasternExtended Trading$14.61 -0.01 (-0.07%) As of 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft's Outlook Brightens as Analysts Boost Bullish Ratings Palantir Scores First $1 Billion Contract; Is It Priced In? Tesla: Why Analysts Think It Could Jump Another 47% Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook 3 Dividend Stocks to Get You Through Tariff Volatility Apple Sinks After New 25% Tariff Announcement—What's The Bottom? MarketBeat Week in Review – 05/19 - 05/23 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
